enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene - Slideshow

🇺🇸 Seeking Alpha (US) —

AI Summary

enGene Therapeutics discussed updated LEGEND study data and the regulatory path for its drug candidate detalimogene. The source description provides no further details about the data or regulatory plans.

Markets Health enGene Therapeutics detalimogene LEGEND study clinical data regulatory pathway

Read original source →